Proenkephalin

Mechanism of Action

• Tissue-specific PC1/PC2 cleavage generates 6 distinct opioid peptides from PENK: 4 met-enkephalin copies, 1 leu-enkephalin, plus 2 C-terminally extended forms (MEAP, MEAGL)
• Adrenal medulla: PENK co-released with catecholamines during stress; adrenal enkephalins suppress cardiovascular response to excessive sympathetic activation
• Kidney PENK expression: adrenal-independent; renal PENK/enkephalin system regulates tubular sodium reabsorption via DOR in collecting duct
• PENKid (proenkephalin aa119-159): stable plasma fragment that reflects renal PENK production; plasma PENKid correlates tightly with GFR
• Cardiac: PENK-derived met-enkephalin exerts negative chronotropic and cardioprotective effects via cardiac DOR

Research Findings

• Plasma PENKid is a novel biomarker of acute kidney injury: rises before creatinine, predicts AKI in ICU patients (GENIUS-AKI trial)
• PENKid above 74 pmol/L in emergency patients associated with 90-day mortality and need for dialysis (GREAT study)
• PENK knockout mice show reduced basal pain thresholds and impaired opioid tolerance development, confirming its role in endogenous opioid tone
• Adrenal PENK gene expression induced by glucocorticoids and CRH; stress-activated PENK forms part of the HPA axis negative feedback at peripheral level
• PENKid added predictive value beyond troponin and BNP for 30-day mortality in acute coronary syndrome patients

Research Protocols

• PENKid plasma biomarker: ELISA-based measurement; reference range <80 pmol/L; cut-offs for AKI and mortality risk vary by study
• PENK gene expression: qPCR on adrenal or kidney tissue following stress, CRH, or glucocorticoid stimulation in rodents
• DOR assay: PENK-derived met-enkephalin/leu-enkephalin as reference agonists in DOR binding or functional assays
• Cardiac PENK: intracoronary met-enkephalin derived from PENK; measure cardiac function changes in isolated heart preparations

Interactions

• PC1/PC2 prohormone convertases: required for all active peptide liberation from PENK; PC1/PC2 expression levels set the tissue enkephalin supply
• Low-dose naltrexone: blocks DOR/OGFr, triggering OGF rebound from PENK neurons; mechanism of LDN immunomodulation
• Corticosteroids/CRH: transcriptional inducers of PENK gene in adrenal medulla; stress increases PENK-derived enkephalin release

Safety Profile

Proenkephalin itself is not therapeutic. PENKid is a diagnostic biomarker. PENK-derived opioid peptides (met/leu-enkephalin) are endogenous with well-characterized safety; rapid degradation limits systemic toxicity.

Legal & Regulatory

PENK itself is a research reagent. PENKid ELISA: research-use biomarker assay; regulatory submissions pending for clinical AKI diagnostic use.